Articles by Christopher H. Lieu, MD
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): a prospective phase 2/3 trial of MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches using ctDNA status as a surrogate for MRD status (NRG-GI008) (NCT05174169).
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US
ByIbrahim Halil Sahin, MD,Yan Lin, PhD,Greg Yothers, PhD,Peter C. Lucas, MD, PhD,Dustin Deming, MD,Thomas J. George, MD,Scott Kopetz, MD, PhD,Christopher H. Lieu, MD,Arvind Dasari, MD, MS Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
